Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 18/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4330902 | 0.85 | TLR7 (0.37) | SMN1; SMN2TLR7 | |
| SCHEMBL2895018 | 0.81 | TLR7 (0.41) | TLR7 | |
| SCHEMBL3093082 | 0.81 | GNRHR (0.39) | TLR7 | |
| SCHEMBL2892852 | 0.80 | TLR7 (0.40) | TLR7 | |
| SCHEMBL1486751 | 0.79 | TLR7 (0.42) | TLR7 | |
| SCHEMBL1948125 | 0.77 | CNR2 (0.39) | TLR7 | |
| SCHEMBL1952878 | 0.76 | CNR2 (0.44) | TLR7 | |
| SCHEMBL1951717 | 0.76 | PIM1 (0.44) | TLR7 | |
| SCHEMBL20796986 | 0.74 | SMN1; SMN2 (0.37) | SMN1; SMN2TLR7 | |
| SCHEMBL30851280 | 0.74 | SMN1; SMN2 (0.37) | SMN1; SMN2TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050148620-A1 | Sulfonamido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148620-A1 | Sulfonamido ether substituted imidazoquinolines | IFNG, IRF3, IL2 | SMN1; SMN2 2320/4885TLR7 24/4885PTGER4 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.